An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
Vaccine
; 17(23-24): 2999-3006, 1999 Aug 06.
Article
in En
| MEDLINE
| ID: mdl-10462235
ABSTRACT
Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject-blinded study, adults (> or = 18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 13439 and 158 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pertussis Vaccine
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Animals
/
Female
/
Humans
/
Male
/
Middle aged
/
Pregnancy
Language:
En
Journal:
Vaccine
Year:
1999
Document type:
Article
Affiliation country: